Multikinase inhibitors use in differentiated thyroid carcinoma

Sina Jasim,1,* Levent Ozsari,2,* Mouhammed Amir Habra2 1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA; 2Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA *These authors con...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jasim S, Ozsari L, Habra MA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/a7502555b4a34c08a0e8a768baff9287
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a7502555b4a34c08a0e8a768baff9287
record_format	dspace
spelling	oai:doaj.org-article:a7502555b4a34c08a0e8a768baff92872021-12-02T00:04:15ZMultikinase inhibitors use in differentiated thyroid carcinoma1177-5491https://doaj.org/article/a7502555b4a34c08a0e8a768baff92872014-12-01T00:00:00Zhttp://www.dovepress.com/multikinase-inhibitors-use-in-differentiated-thyroid-carcinoma-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491 Sina Jasim,1,* Levent Ozsari,2,* Mouhammed Amir Habra2 1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA; 2Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA *These authors contributed equally in this work Abstract: Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemic therapy for metastatic disease. Patients with metastatic DTC do not usually benefit from traditional cytotoxic chemotherapy. In this review, we describe newly developed small-molecule tyrosine kinase inhibitors (TKIs) that are being actively tested and used in the management of advanced thyroid cancer. The use of TKIs as a form of molecular targeted therapy is evolving based on understanding of the pathways involved in DTC. Disrupting tumor vascular supply by targeting vascular endothelial growth factor receptor signaling is the most commonly used approach to treat advanced/metastatic DTC. Other mechanisms include targeting BRAF, MAPK/ERK kinase, or mammalian target of rapamycin signaling. Although TKIs appear to have superior efficacy compared to cytotoxic chemotherapy, they can cause substantial adverse effects; symptomatic management of adverse effects, dose adjustment, or cessation of therapy may be required. Keywords: differentiated thyroid cancer, progression-free survival, adverse effects, targeted therapy, sorafenib, lenvatinibJasim SOzsari LHabra MADove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2014, Iss default, Pp 281-291 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Jasim S Ozsari L Habra MA Multikinase inhibitors use in differentiated thyroid carcinoma
description	Sina Jasim,1,* Levent Ozsari,2,* Mouhammed Amir Habra2 1Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA; 2Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA *These authors contributed equally in this work Abstract: Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing. Standard therapy for most patients with localized differentiated thyroid cancer (DTC) includes surgery, radioactive iodine, and thyroid hormone replacement. A minority of thyroid cancer patients requires systemic therapy for metastatic disease. Patients with metastatic DTC do not usually benefit from traditional cytotoxic chemotherapy. In this review, we describe newly developed small-molecule tyrosine kinase inhibitors (TKIs) that are being actively tested and used in the management of advanced thyroid cancer. The use of TKIs as a form of molecular targeted therapy is evolving based on understanding of the pathways involved in DTC. Disrupting tumor vascular supply by targeting vascular endothelial growth factor receptor signaling is the most commonly used approach to treat advanced/metastatic DTC. Other mechanisms include targeting BRAF, MAPK/ERK kinase, or mammalian target of rapamycin signaling. Although TKIs appear to have superior efficacy compared to cytotoxic chemotherapy, they can cause substantial adverse effects; symptomatic management of adverse effects, dose adjustment, or cessation of therapy may be required. Keywords: differentiated thyroid cancer, progression-free survival, adverse effects, targeted therapy, sorafenib, lenvatinib
format	article
author	Jasim S Ozsari L Habra MA
author_facet	Jasim S Ozsari L Habra MA
author_sort	Jasim S
title	Multikinase inhibitors use in differentiated thyroid carcinoma
title_short	Multikinase inhibitors use in differentiated thyroid carcinoma
title_full	Multikinase inhibitors use in differentiated thyroid carcinoma
title_fullStr	Multikinase inhibitors use in differentiated thyroid carcinoma
title_full_unstemmed	Multikinase inhibitors use in differentiated thyroid carcinoma
title_sort	multikinase inhibitors use in differentiated thyroid carcinoma
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/a7502555b4a34c08a0e8a768baff9287
work_keys_str_mv	AT jasims multikinaseinhibitorsuseindifferentiatedthyroidcarcinoma AT ozsaril multikinaseinhibitorsuseindifferentiatedthyroidcarcinoma AT habrama multikinaseinhibitorsuseindifferentiatedthyroidcarcinoma
_version_	1718403947061837824

Multikinase inhibitors use in differentiated thyroid carcinoma

Ejemplares similares